UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

Annals of oncology, 2011-07, Vol.22 (7), p.1535-1546

2011

Volltextzugriff (PDF)

Transient MEK inhibitor-associated retinopathy in metastatic melanoma

Annals of oncology, 2014-07, Vol.25 (7), p.1437-1441

2014

Volltextzugriff (PDF)

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

British journal of cancer, 2014-10, Vol.111 (9), p.1788-1801

2014

Volltextzugriff (PDF)

Interpreting progression-free survival and overall survival data in biosimilar clinical studies: considerations based on a recent rituximab biosimilar study

ANNALS OF ONCOLOGY, 2017-09, Vol.28, p.v361-v361

2017

Volltextzugriff (PDF)

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group

Annals of oncology, 2008-08, Vol.19 (8), p.1442-1449

2008

Volltextzugriff (PDF)

Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4003-4003

2007

Volltextzugriff (PDF)

Equivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study

Annals of oncology, 2017-09, Vol.28, p.v355-v355

2017

Volltextzugriff (PDF)

3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS

European journal of cancer supplements, 2007-09, Vol.5 (4), p.236-236

2007

Volltextzugriff (PDF)

6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4± cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study

European journal of cancer supplements, 2009, Vol.7 (2), p.346-346

2009

Volltextzugriff (PDF)

6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial

European journal of cancer supplements, 2009, Vol.7 (2), p.345-345

2009

Volltextzugriff (PDF)

CLINICAL SIGNIFICANCE OF AMBULATORY BLOOD PRESSURE MONITORING AND CIRCADIAN SYNTHESIS OF MELATONIN IN PREDICTING OBSTRUCTIVE SLEEP APNEA SYNDROME IN PATIENTS WITH GRADE 1-2 ARTERIAL HYPERTENSION

Zhurnal Grodnenskogo gosudarstvennogo medit͡s︡inskogo universiteta, 2024-07, Vol.22 (3), p.250-257

2024

Volltextzugriff (PDF)

3003 ORAL Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial

European journal of cancer supplements, 2007, Vol.5 (4), p.235-236

2007

Volltextzugriff (PDF)

Overall Survival and Biomarker Results from a Phase 2 Study of Mek1/2 Inhibitor Binimetinib (Mek162) in Patients with Advanced Nras-Mutant Melanoma

Annals of oncology, 2014-09, Vol.25, p.v1

2014

Volltextzugriff (PDF)

LBA35OVERALL SURVIVAL AND BIOMARKER RESULTS FROM A PHASE 2 STUDY OF MEK1/2 INHIBITOR BINIMETINIB (MEK162) IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA

Annals of oncology, 2014-09, Vol.25 (suppl_4)

2014

Volltextzugriff (PDF)

Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.PD01-01-PD01-01

2010

Volltextzugriff (PDF)

Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.4076-4076

2009

Volltextzugriff (PDF)

Transient MEK inhibitor-associated retinopathy in metastatic melanoma

Annals of oncology, 2014-07, Vol.25 (7), p.1437

2014

Volltextzugriff (PDF)

Cetuximab in combination with weekly 5-fluorouracil/ folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer : a phase Ib/II study of the AIO Gl Group

Annals of oncology, 2008, Vol.19 (8), p.1442-1449

2008

Volltextzugriff (PDF)

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4035-4035

2007

Volltextzugriff (PDF)

Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3556-3556

2006

Volltextzugriff (PDF)

Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3085-3085

2006

Volltextzugriff (PDF)

Anisotropic etching of Si

Journal of micromechanics and microengineering, 2019-09, Vol.29 (9), p.93002

Zubel, Irena

2019

Volltextzugriff (PDF)

Effect of cations on silicon anisotropic etching process in solutions containing TMAH and TMAH with tensioactive compounds

Sensors and actuators. A. Physical., 2020-03, Vol.303, p.111829, Article 111829

Zubel, Irena

2020

Volltextzugriff (PDF)

1523: CASE OF BRASH SYNDROME REQUIRING DIALYSIS

Critical care medicine, 2024-01, Vol.52 (1), p.S732-S732

2024

Volltextzugriff (PDF)

From decolonization to destalinization: Aimé Césaire and the "Polish question"

Journal of postcolonial writing, 2023-03, Vol.59 (2), p.157-171

Zubel, Marla

2023

Volltextzugriff (PDF)

1 – 25 von 213

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(153)
Mit Volltextzugriff
(149)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(94)
Life Sciences & Biomedicine
(47)
Technology
(42)
Humans
(38)
Engineering
(31)
Female
(26)
Engineering, Electrical & Electronic
(25)
Physical Sciences
(25)
Physics
(25)
Male
(22)
Middle Aged
(21)
Aged
(20)
Exact Sciences And Technology
(20)
Adult
(18)
Instruments & Instrumentation
(18)
Animals
(15)
Oncology
(14)
Silicon
(14)
Anisotropic Etching
(13)
Materials Science
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

Transient MEK inhibitor-associated retinopathy in metastatic melanoma

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

Interpreting progression-free survival and overall survival data in biosimilar clinical studies: considerations based on a recent rituximab biosimilar study

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group

Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial

Equivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study

3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS

6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4± cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study

6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial

CLINICAL SIGNIFICANCE OF AMBULATORY BLOOD PRESSURE MONITORING AND CIRCADIAN SYNTHESIS OF MELATONIN IN PREDICTING OBSTRUCTIVE SLEEP APNEA SYNDROME IN PATIENTS WITH GRADE 1-2 ARTERIAL HYPERTENSION

3003 ORAL Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial

Overall Survival and Biomarker Results from a Phase 2 Study of Mek1/2 Inhibitor Binimetinib (Mek162) in Patients with Advanced Nras-Mutant Melanoma

LBA35OVERALL SURVIVAL AND BIOMARKER RESULTS FROM A PHASE 2 STUDY OF MEK1/2 INHIBITOR BINIMETINIB (MEK162) IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA

Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial

Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial

Transient MEK inhibitor-associated retinopathy in metastatic melanoma

Cetuximab in combination with weekly 5-fluorouracil/ folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer : a phase Ib/II study of the AIO Gl Group

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study

Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC)

Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC)

Anisotropic etching of Si

Effect of cations on silicon anisotropic etching process in solutions containing TMAH and TMAH with tensioactive compounds

1523: CASE OF BRASH SYNDROME REQUIRING DIALYSIS

From decolonization to destalinization: Aimé Césaire and the "Polish question"

Suchergebnisse filtern